Genenta Science S.R.L.   Report issue

For profit Phase 2
Founded: Milano Italy (2014)

Organization Overview

First Clinical Trial
2019
NCT03866109
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Genenta Science

Active Ingredients

Drugs in Phase 2 Trials (1)

temferon (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1